4See Ventures

PowerAPI is a developer of a management platform designed to assist businesses with point-of-sale solutions and streamline their technology development through user-friendly low-code modules. The company provides white-label, plug-and-play tools that facilitate digitalization for corporates, service and product integrators, agencies, and the public sector. PowerAPI's offerings enable clients to enhance their product offerings, meet customer needs, and expedite their go-to-market processes. Additionally, the platform serves as an all-in-one operational software for small and medium-sized businesses, allowing them to manage their entire technology stack, automate operations, simplify administrative tasks, and drive online revenue growth. With a focus on partner success, PowerAPI ensures top-class support for its users, helping them to seize new business opportunities effectively.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

CYSEC is a startup focused on advancing Confidential Computing solutions that ensure the security of data at rest, in motion, and in use. The company has developed a cloud-based data security software that operates as a physical enterprise-grade server appliance, enabling businesses to safeguard their assets and maintain the integrity and confidentiality of data stored in the cloud. CYSEC's flagship product, the ARCA solution, has gained popularity in the market due to its ability to support multiple applications and enhance cybersecurity across various sectors. By providing innovative tools for confidential computing, CYSEC aims to empower organizations to develop cutting-edge technological solutions while ensuring robust data protection.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

keepMED Ltd. is a medical technology company based in Rishon Le Zion, Israel, dedicated to developing innovative solutions for the treatment of Obstructive Sleep Apnea (OSA). Founded in 2012 and formerly known as Ninox Medical Ltd., the company has created keePAP, a wearable device designed to address the challenges associated with OSA. This device features a lightweight and unobtrusive nasal interface paired with a compact, battery-operated control unit, allowing for effective management of upper airway obstruction during sleep. Through its focus on disruptive technology, keepMED aims to improve the quality of life for individuals affected by this common sleep disorder.